Company news: Pfizer, IMS Health and Elsevier
Phase II tofacitinib results show Pfizer's drug may be suited for the ulcerative colitis market, IMS Health acquires a benchmarking ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.